Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.

Anti-cancer drugs - 1 Jul 2007

Liu Jackie Yao, Qu Kevin, Sferruzza Anthony D, Bender Richard A

Abstract excerpt

The hepatic isoform 1A1 of uridine diphosphate glucuronosyltransferase is responsible for glucuronidation and detoxification of SN-38, the active metabolite of irinotecan. The presence of an additional TA repeat in the TATA sequence of the UGT1A1 promoter leads to a significant decrease in SN-38 glucuronidation. Patients with the UGT1A1 (TA)7 allele are more likely to experience severe neutropenia and diarrhea...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Asian

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Metabolic Clearance Rate

Share to Philippines

Share to United States

Source

Identifiers

PMID: 17762398
DOI: 10.1097/CAD.0b013e32803a46fe

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.PMID 17762398Read ↗

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.Semantic proximity Read ↗

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.Semantic proximity Read ↗

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.Semantic proximity Read ↗

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.Semantic proximity Read ↗

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.Semantic proximity Read ↗

Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.Semantic proximity Read ↗

UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.Semantic proximity Read ↗

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28Semantic proximity Read ↗

Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populations.Semantic proximity Read ↗

The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions.Semantic proximity Read ↗

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.Semantic proximity Read ↗

Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.